$MCRB

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 - Seres Therapeutics (NASDAQ:MCRB)

CAMBRIDGE, Mass., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Seres Therapeutics, Inc. ( NASDAQ:MCRB ) , a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m.

Original reporting
Benzinga · Globe Newswire
Published Oct 30, 2025, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 30, 2025, 11:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 - Seres Therapeutics (NASDAQ:MCRB) — source image
Decision brief

The 30-second read

$MCRBNeutralMed
01

Why it matters

The announcement could cause increased trading volume and volatility, especially if results differ markedly from expectations.

02

Market read

High relevance for biotech investors; moderate relevance for general market participants.

03

What to watch

Market sentiment may be influenced by broader biotech sector trends or macroeconomic factors unrelated to the earnings.

Timing: High; event scheduled for November 5, 2025, with potential for short-term trading opportunities.

Background

Seres Therapeutics is a biotech company specializing in live biotherapeutics. The upcoming earnings report is a key event for investors.

Company-level read

Ticker impact

$MCRBNeutralMedium confidence
Context

High relevance due to upcoming earnings announcement and management event.

Expected impact

Potential short-term increase or decrease depending on earnings results; medium probability of significant movement.

Evidence & confidence

Earnings announcements typically influence stock prices; however, without prior earnings data or guidance, the impact remains uncertain.

Market effects

Positive sentiment for biotech and live biotherapeutics sector if results surpass expectations.

Potential volatility in US biotech stocks; global markets may experience ripple effects.

Limited; primarily regional impact unless results are significantly groundbreaking.

Counterpoint

Disappointing results could lead to sharp declines, presenting short-selling opportunities.

Key entities

  • Seres Therapeutics

    A leading biotech firm focused on microbiome therapeutics.

Related articles

$MCRBMed

Seres Therapeutics, Inc. (MCRB): Results of Operations and Financial Condition

Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d124829dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS Recently announced 80% of SER-155 recipients achieved immunosuppres

$AAPLMed

Apple Tests Chinese Memory Chips As Supply Crunch Pushes PC Giants Toward CXMT

The Wall Street Journal reported Apple is testing memory chips from China’s CXMT across iPhones and MacBooks and has held early talks to supply components for some China-sold devices. Apple is seeking White House approval amid “unsustainable” pricing from SK Hynix, Samsung, Micron and SanDisk. US rules limit customization, but off-the-shelf purchases may be allowed.

$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.